487 related articles for article (PubMed ID: 23682925)
21. DNA damage response inhibitors: An avenue for TNBC treatment.
Jin J; Tao Z; Cao J; Li T; Hu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
[TBL] [Abstract][Full Text] [Related]
22. Breaking the DNA damage response to improve cervical cancer treatment.
Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
[TBL] [Abstract][Full Text] [Related]
23. Targeting the DNA Damage Response in Cancer.
O'Connor MJ
Mol Cell; 2015 Nov; 60(4):547-60. PubMed ID: 26590714
[TBL] [Abstract][Full Text] [Related]
24. DNA damage response regulation by microRNAs as a therapeutic target in cancer.
Majidinia M; Yousefi B
DNA Repair (Amst); 2016 Nov; 47():1-11. PubMed ID: 27697364
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
[TBL] [Abstract][Full Text] [Related]
26. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
Arjumand W; Asiaf A; Ahmad ST
Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
[TBL] [Abstract][Full Text] [Related]
27. Emerging therapeutic aspects in oncology.
Macewan DJ
Br J Pharmacol; 2013 Aug; 169(8):1647-51. PubMed ID: 23889318
[TBL] [Abstract][Full Text] [Related]
28. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
29. Review: Protein O-GlcNAcylation regulates DNA damage response: A novel target for cancer therapy.
Zhu Z; Li S; Yin X; Sun K; Song J; Ren W; Gao L; Zhi K
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130351. PubMed ID: 38403231
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach.
Lodovichi S; Cervelli T; Pellicioli A; Galli A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932697
[TBL] [Abstract][Full Text] [Related]
31. Targeting homologous recombination repair defects in cancer.
Evers B; Helleday T; Jonkers J
Trends Pharmacol Sci; 2010 Aug; 31(8):372-80. PubMed ID: 20598756
[TBL] [Abstract][Full Text] [Related]
32. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.
Bouwman P; Jonkers J
Nat Rev Cancer; 2012 Sep; 12(9):587-98. PubMed ID: 22918414
[TBL] [Abstract][Full Text] [Related]
33. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies.
Mirza-Aghazadeh-Attari M; Ostadian C; Saei AA; Mihanfar A; Darband SG; Sadighparvar S; Kaviani M; Samadi Kafil H; Yousefi B; Majidinia M
DNA Repair (Amst); 2019 Aug; 80():59-84. PubMed ID: 31279973
[TBL] [Abstract][Full Text] [Related]
34. Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer.
Wu Z; Li S; Tang X; Wang Y; Guo W; Cao G; Chen K; Zhang M; Guan M; Yang D
Theranostics; 2020; 10(9):3939-3951. PubMed ID: 32226530
[No Abstract] [Full Text] [Related]
35. Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy.
Li L; Kumar AK; Hu Z; Guo Z
Curr Med Chem; 2021; 28(5):963-985. PubMed ID: 32091326
[TBL] [Abstract][Full Text] [Related]
36. DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.
Carrassa L; Damia G
Cancer Treat Rev; 2017 Nov; 60():139-151. PubMed ID: 28961555
[TBL] [Abstract][Full Text] [Related]
37. [Synthetic lethality as a new concept for the treatment of cancer].
Herter-Sprie GS; Chen S; Höpker K; Reinhardt HC
Dtsch Med Wochenschr; 2011 Jul; 136(30):1526-30. PubMed ID: 21789751
[TBL] [Abstract][Full Text] [Related]
38. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
39. To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response.
Liu Q; Gao J; Zhao C; Guo Y; Wang S; Shen F; Xing X; Luo Y
DNA Repair (Amst); 2020 Jan; 85():102702. PubMed ID: 31731257
[TBL] [Abstract][Full Text] [Related]
40. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
Hu Y; Guo M
Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
